查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016463

非專利注射市場報告：按治療領域、包裝容器、分銷管道和地區分類（2026-2034 年）

Generic Injectables Market Report by Therapeutic Area, Container, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球非專利注射劑市場規模達545億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到1,003億美元，2026年至2034年的複合年成長率為6.67%。品牌藥專利到期數量的增加，以及政府機構監管力度的加大，是推動成長要素。

非專利注射劑是指劑量、效力、品質和療效與品牌藥相同的注射用藥物。這包括多種藥物，例如疫苗、胰島素和抗生素。非專利注射劑廣泛用於治療多種疾病，包括糖尿病、癌症、高血壓和感染疾病。它們在麻醉、荷爾蒙補充療法、疫苗接種和急診醫學等領域也有廣泛的應用。非專利注射劑安全且經濟有效，可減少手術介入的需求，提供標靶治療，並減少副作用。

近年來，製劑和給藥系統技術的進步提高了生產效率，降低了成本並擴大了供應，從而推動了市場成長。此外，各項監管支援措施和舉措，例如簡化核准流程，為非專利注射劑生產商創造了有利的營商環境，也促進了市場成長。同時，老年人口的成長也對市場成長產生了積極影響，老年人需要更多的醫療干預，包括針對各種老齡化疾病的注射藥物。此外，由於注射藥物起效迅速、生物利用度高，患者越來越傾向於選擇注射藥物而非口服藥物，這也推動了市場成長。此外，供應鏈的快速改進提高了非專利注射劑的分銷效率，進一步促進了市場成長。

非專利注射劑藥物市場的趨勢和促進因素：

慢性病盛行率正在迅速上升。

慢性病盛行率的上升是非專利注射劑市場發展的主要動力。癌症、糖尿病和心血管疾病等疾病的發生率持續上升，需要長期治療和藥物。用於治療糖尿病的胰島素、用於治療癌症的化療藥物以及用於治療心血管疾病的降血壓藥物等非專利注射劑對於控制這些疾病至關重要。此外，非專利注射劑價格低廉，使更多人能夠獲得這些藥物。這項優勢在醫療基礎設施有限或醫療成本較高的中低收入國家尤為顯著。同時，醫療衛生系統也越來越重視品質和成本效益之間的平衡。因此，非專利注射劑成為一種切實可行的選擇，因為它們能夠以遠低於品牌藥的價格提供必要的治療。這將有助於更廣泛地管理和控制疾病。

全球醫療保健支出正在增加。

醫療保健成本不斷上漲是已開發國家和開發中國家共同面臨的主要問題。隨著治療費用飆升，人們迫切需要價格合理的替代方案。在此背景下，非專利注射劑提供了一種經濟有效的解決方案，且不會影響療效或安全性。此外，它們還能顯著減輕患者及其家庭的經濟負擔。同時，它們也能幫助預算有限的醫療系統更有效地分配資源，進而改善醫療服務、進行研究並推動公共衛生計畫。患者也能直接受益於自付費用減少和就醫便利。因此，不斷上漲的醫療保健成本正迫使醫療服務提供者和患者轉向非專利注射劑，將其作為經濟永續的替代方案。

品牌藥專利到期增加

品牌注射專利到期為非專利藥注射劑市場帶來了巨大的機會。專利到期後，學名藥生產商可以生產和銷售品牌藥的仿製品。此外，由於他們無需承擔前期研發成本即可生產同等療效的藥物，因此可以將節省的成本以更低的價格回饋給消費者。另外，由於學名藥與已核准的品牌藥具有生物等效性，因此通常能更快獲得監管部門的核准。這不僅縮短了上市時間，也擴大了消費者取得基本藥物的途徑。此外，專利到期使得先前受智慧財產權法限制的藥物得以大規模生產。因此，專利到期為非專利藥注射劑市場的擴張創造了有利環境，使生產商和消費者都從中受益。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球非專利注射劑市場

  • 市場概覽
  • 市場表現
  • 市場區隔：按地區
  • 市場預測
  • 主要企業

第6章：全球非專利注射劑市場

  • 口服
  • 注射藥物
  • 經皮/局部用藥
  • 吸入器

第7章：全球非專利注射劑市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場區隔：按地區
  • 市場區隔：按治療區域
  • 市場區隔：依貨櫃類型
  • 市場區隔：依分銷通路分類
  • 市場預測
  • SWOT分析
  • 價值鏈分析
  • 波特五力分析
  • 關鍵市場促進因素與成功因素

第8章 全球非專利注射劑市場：主要地區趨勢

  • 北美洲
  • 歐洲
  • 亞洲
  • 拉丁美洲
  • 中東和非洲

第9章 市場：依治療領域分類

  • 腫瘤學
  • 麻醉
  • 感染疾病物
  • 腸外營養
  • 循環系統

第10章 市場：依貨櫃分類

  • 管瓶
  • 安瓿
  • 預混合料
  • 預填充式注射器

第11章 市場：依分銷管道分類

  • 醫院
  • 零售藥房

第12章 全球非專利注射劑藥物市場：競爭格局

  • 市場結構
  • 市場區隔：依主要企業分類

第13章：非專利注射藥物生產流程

第14章：項目詳情、需求及相關成本

第15章 貸款與財務支持

第16章 專案經濟學

第17章：主要企業概況

  • AstraZeneca plc
  • Baxter International, Inc.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals plc
  • Lupin Ltd.
  • Pfizer, Inc.
  • Sandoz AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: SR112026A804

The global generic injectables market size reached USD 54.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 100.3 Billion by 2034, exhibiting a growth rate (CAGR) of 6.67% during 2026-2034. The growing patent expiration of branded drugs, along with the increasing regulatory support from government bodies, is primarily driving the market.

Generic injectables refer to pharmaceutical drugs that are injected into the body and are equivalent to their brand-name counterparts in dosage, strength, quality, and performance. It includes various types, such as vaccines, insulin, and antibiotics. Generic injectables are widely used for a range of medical conditions, such as diabetes, cancer, hypertension, and infections. They also find extensive applications in anesthesia, hormone replacement, immunization, and emergency treatments. Generic injectables are safe and cost-effective medications that reduce the need for surgical interventions, provide targeted therapy, and have fewer side effects.

The recent technological advancements in drug formulation and delivery systems that are making production more efficient, thereby lowering costs and boosting availability, are propelling the market growth. Additionally, the implementation of various regulatory support and initiatives to create a conducive environment for manufacturers of generic injectables by streamlining approval processes is contributing to the market growth. Apart from this, the growing geriatric population, which requires more healthcare interventions, including injectables for various age-related ailments, is positively influencing the market growth. Furthermore, the rising preference for injectables over oral medications among patients due to quicker onset of action and higher bioavailability is strengthening the market growth. In addition, the rapid improvement in the supply chain, which has made the distribution of generic injectables more streamlined, is supporting the market growth.

Generic Injectables Market Trends/Drivers:

The escalating prevalence of chronic diseases

The escalating prevalence of chronic diseases is a primary driver of the generic injectables market. Conditions such as cancer, diabetes, and cardiovascular diseases (CVDs) are on a constant rise and require long-term treatments and medications. Generic injectables such as insulin for diabetes, chemotherapeutic agents for cancer, and antihypertensive medications for cardiovascular issues are indispensable in the management of these conditions. Furthermore, the affordability of generic injectables makes them accessible to a larger population, especially in low and middle-income countries where healthcare infrastructure may be limited or costly. Additionally, healthcare systems are focusing on balancing quality and cost-effectiveness. In line with this, generic injectables present a viable option, as they provide the necessary treatments at a fraction of the cost of their branded counterparts, thus facilitating more widespread disease management and containment.

The rising healthcare expenditure across the globe

The growing cost of healthcare is a significant concern for both developed and developing nations. There is an urgent need for affordable alternatives as treatment expenses are skyrocketing. In line with this, generic injectables offer a cost-effective solution without compromising on efficacy or safety. Furthermore, they can substantially lower the economic burden on patients and families. Additionally, they provide budget-constrained healthcare systems with the leeway to allocate resources more efficiently towards the improvement of healthcare services, research, or public health initiatives. Moreover, patients also benefit directly through lower out-of-pocket costs, making treatments more accessible. As a result, the rising cost of healthcare is compelling healthcare providers and patients to turn to generic injectables as a financially sustainable alternative.

The increasing patent expiration of branded drugs

Patent expirations of branded injectables present a golden opportunity for the generic injectables market. Expiry of the patent allows generic drug manufacturers to produce and sell copies of the branded medication. Furthermore, they can produce equivalent medications without incurring the initial research and development (R&D) costs, thereby passing on the savings to the consumers in the form of lower prices. Moreover, the generic versions usually receive faster regulatory approvals as they are bioequivalent to already-approved branded drugs. This not only speeds up the time-to-market but also broadens consumer access to essential medications. Additionally, patent expiry enables the mass production of medications that were previously restricted by intellectual property (IP) laws. As a result, patent expiration creates a conducive environment for the expansion of the generic injectables market, benefiting both manufacturers and consumers.

Generic Injectables Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global generic injectables market report, along with forecasts at the global, and regional levels for 2026-2034. Our report has categorized the market based on therapeutic area, container, and distribution channel.

Breakup by Therapeutic Area:

  • Oncology
  • Anaesthesia
  • Anti-infectives
  • Parenteral Nutrition
  • Cardiovascular

Oncology dominates the market

Oncology is dominating the market due to the high prevalence of cancer, which necessitates a consistent and accessible supply of medications for treatment. Furthermore, cancer treatments are highly expensive, often requiring combinations of drugs and long-term administration. In line with this, generic injectables offer a cost-effective alternative to branded drugs, alleviating some of the financial burdens on healthcare systems and patients. Besides this, the oncology sector has witnessed patent expirations for branded drugs, thus opening up opportunities for generic pharmaceutical companies to introduce their versions of these medications. Moreover, the complexity of cancer treatment protocols, which often call for targeted therapies, is facilitating the demand for generic injectables. In addition, oncology treatments frequently necessitate hospitalization or clinical administration of drugs, where injectables are more commonly used.

Breakup by Container:

  • Vials
  • Ampoules
  • Premix
  • Prefilled Syringes

Vials exhibit a clear dominance in the market

Vials offer a high degree of sterility and contamination protection, which is essential for injectable drugs. The integrity of the medication is better preserved in a vial, which is a critical factor when dealing with sensitive substances, such as biologics or chemotherapy agents. Furthermore, they are incredibly versatile and can accommodate a wide range of drug volumes, from small quantities for specialized treatments to larger volumes for widespread applications. Additionally, vials are highly cost-effective, especially when produced in bulk. This cost advantage aligns well with the overall appeal of generic injectables as cost-effective alternatives to branded drugs.

Ampoules offer high barrier properties, ensuring that the medication inside remains sterile and free from contamination. Additionally, the glass construction of ampoules allows for high visibility, enabling healthcare professionals to visually inspect the solution for any impurities before administration, thus adding an extra layer of safety. Besides this, they are usually single-dose containers, which eliminates the risks associated with multi-dose vials, such as cross-contamination and dosing errors.

Breakup by Distribution Channel:

  • Hospitals
  • Retail Pharmacy

Hospitals holds the largest share in the market

Hospitals are dominating the market as they allow the immediate and precise administration of injectables, which is especially critical in emergency situations or intensive care units (ICUs) where quick onset of action can be lifesaving. Furthermore, they handle a high volume of patients and a broad array of medical conditions, ranging from surgeries to chronic disease management. The versatility of generic injectables allows them to be used across various departments, making them a go-to option for multiple therapeutic applications. Besides this, hospitals have the necessary infrastructure, including temperature-controlled storage and trained medical staff, to manage the complexities of injectable drug administration. Moreover, the growing pressure to manage healthcare costs effectively makes generic injectables a preferred choice for hospitals.

Breakup by Region:

  • Europe
  • North America
  • Asia
  • Latin America
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest generic injectables market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include Europe, North America, Asia, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a well-established healthcare system that readily adopts medical innovations, including generic injectables. Furthermore, the region has some of the highest per capita healthcare spending, allowing for the widespread use of both branded and generic pharmaceuticals. Additionally, the imposition of supportive policies by regional governments to streamline processes for the approval of generic medications, including injectables, is positively influencing the market growth. Besides this, the frequent expiry of branded medication patents in North America is creating opportunities for generic drug manufacturers to introduce their own, more affordable versions. Moreover, the escalating geriatric population, which requires more medical treatments, often leading to higher consumption of medications, including injectables, is acting as another growth-inducing factor. Along with this, the heightened awareness and acceptance among both healthcare providers and consumers regarding the efficacy and cost-effectiveness of generic medications is supporting the market growth.

Competitive Landscape:

Leading companies are consistently working to expand their range of generic injectable medications, including biosimilars, to cover a broader spectrum of therapeutic areas. Furthermore, they are investing in research and innovation to improve the formulation and stability of generic injectables, thereby enhancing their quality and market appeal. In addition, several key players are forming strategic partnerships with other industry stakeholders to enhance their capabilities, distribution networks, and product offerings. Besides this, companies are focusing on expanding their geographical reach through collaboration with local distributors or setting up manufacturing facilities. Additionally, they are working on optimizing their production processes to offer cost-effective solutions without compromising on quality. Moreover, major players are ensuring products meet the rigorous regulatory requirements, especially in highly regulated markets.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.

Some of the key players in the market include:

  • Baxter International Inc.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals plc
  • Pfizer Inc.
  • Sagent Pharmaceuticals Inc. (Nichi-Iko Pharmaceutical Co. Ltd.)
  • Sandoz International GmbH (Novartis International AG)
  • Sanofi S.A.

Key Questions Answered in This Report

1. What was the size of the global generic injectables market in 2025?

2. What is the expected growth rate of the global generic injectables market during 2026-2034?

3. What has been the impact of COVID-19 on the global generic injectables market?

4. What are the key factors driving the global generic injectables market?

5. What is the breakup of the global generic injectables market based on the therapeutic area?

6. What is the breakup of the global generic injectables market based on the distribution channel?

7. What are the key regions in the global generic injectables market?

8. Who are the key players/companies in the global generic injectables market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Generic Drug Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Market Breakup by Region
  • 5.4 Market Forecast
  • 5.5 Major Players

6 Global Generic Drug Delivery Market

  • 6.1 Oral
  • 6.2 Injectables
  • 6.3 Dermal/Topical
  • 6.4 Inhalers

7 Global Generic Injectables Market

  • 7.1 Market Overview
  • 7.2 Market Performance
  • 7.3 Impact of COVID-19
  • 7.4 Market Breakup by Region
  • 7.5 Market Breakup by Therapeutic Area
  • 7.6 Market Breakup by Container
  • 7.7 Market Breakup by Distribution Channel
  • 7.8 Market Forecast
  • 7.9 SWOT Analysis
    • 7.9.1 Overview
    • 7.9.2 Strengths
    • 7.9.3 Weaknesses
    • 7.9.4 Opportunities
    • 7.9.5 Threats
  • 7.10 Value Chain Analysis
  • 7.11 Porter's Five Forces Analysis
    • 7.11.1 Overview
    • 7.11.2 Bargaining Power of Buyers
    • 7.11.3 Bargaining Power of Suppliers
    • 7.11.4 Degree of Competition
    • 7.11.5 Threat of New Entrants
    • 7.11.6 Threat of Substitutes
  • 7.12 Key Market Drivers and Success Factors

8 Global Generic Injectables Market: Performance of Key Regions

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market by Therapeutic Area

  • 9.1 Oncology
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Anaesthesia
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Anti-infectives
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Parenteral Nutrition
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Cardiovascular
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market by Container

  • 10.1 Vials
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Ampoules
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Premix
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Prefilled Syringes
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market by Distribution Channel

  • 11.1 Hospitals
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacy
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast

12 Global Generic Injectables Market: Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Market Breakup by Key Players

13 Generic Injectables Manufacturing Process

  • 13.1 Product Overview
  • 13.2 Detailed Process Flow (Injectables)
  • 13.3 Various Types of Unit Operations Involved
  • 13.4 Mass Balance and Raw Material Requirements

14 Project Details, Requirements and Costs Involved

  • 14.1 Land Requirements and Expenditures
  • 14.2 Construction Requirements and Expenditures
  • 14.3 Plant Machinery
  • 14.4 Machinery Pictures
  • 14.5 Raw Material Requirements and Expenditures
  • 14.6 Packaging Requirements and Expenditures
  • 14.7 Transportation Requirements and Expenditures
  • 14.8 Utility Requirements and Expenditures
  • 14.9 Manpower Requirements and Expenditures
  • 14.10 Other Capital Investments

15 Loans and Financial Assistance

16 Project Economics

  • 16.1 Capital Cost of the Project
  • 16.2 Techno-Economic Parameters
  • 16.3 Product Pricing and Margins Across Various Levels of the Supply Chain
  • 16.4 Taxation and Depreciation
  • 16.5 Income Projections
  • 16.6 Expenditure Projections
  • 16.7 Financial Analysis
  • 16.8 Profit Analysis

17 Key Player Profiles

  • 17.1 AstraZeneca plc
    • 17.1.1 Company Overview
    • 17.1.2 Product Portfolio
    • 17.1.3 Financials
    • 17.1.4 SWOT Analysis
  • 17.2 Baxter International, Inc.
    • 17.2.1 Company Overview
    • 17.2.2 Product Portfolio
    • 17.2.3 Financials
    • 17.2.4 SWOT Analysis
  • 17.3 Fresenius SE & Co. KGaA
    • 17.3.1 Company Overview
    • 17.3.2 Product Portfolio
    • 17.3.3 Financials
    • 17.3.4 SWOT Analysis
  • 17.4 Hikma Pharmaceuticals plc
    • 17.4.1 Company Overview
    • 17.4.2 Product Portfolio
    • 17.4.3 Financials
    • 17.4.4 SWOT Analysis
  • 17.5 Lupin Ltd.
    • 17.5.1 Company Overview
    • 17.5.2 Product Portfolio
    • 17.5.3 Financials
    • 17.5.4 SWOT Analysis
  • 17.6 Pfizer, Inc.
    • 17.6.1 Company Overview
    • 17.6.2 Product Portfolio
    • 17.6.3 Financials
    • 17.6.4 SWOT Analysis
  • 17.7 Sandoz AG
    • 17.7.1 Company Overview
    • 17.7.2 Product Portfolio
    • 17.7.3 Financials
    • 17.7.4 SWOT Analysis
  • 17.8 Sun Pharmaceutical Industries Ltd.
    • 17.8.1 Company Overview
    • 17.8.2 Product Portfolio
    • 17.8.3 Financials
    • 17.8.4 SWOT Analysis
  • 17.9 Teva Pharmaceutical Industries Ltd.
    • 17.9.1 Company Overview
    • 17.9.2 Product Portfolio
    • 17.9.3 Financials
    • 17.9.4 SWOT Analysis
  • 17.10 Viatris Inc.
    • 17.10.1 Company Overview
    • 17.10.2 Product Portfolio
    • 17.10.3 Financials
    • 17.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Generic Drug Market: Value Trends (in Billion USD), 2020-2025
  • Figure 2: Global: Generic Drug Market: Breakup by Region (in %), 2025
  • Figure 3: Global: Generic Drug Market Forecast: Value Trends (in Billion USD), 2026-2034
  • Figure 4: Global: Generic Drug Delivery Market: Oral (in Million USD), 2020, 2025 & 2034
  • Figure 5: Global: Generic Drug Delivery Market: Injectables (in Million USD), 2020, 2025 & 2034
  • Figure 6: Global: Generic Drug Delivery Market: Dermal/Topical (in Million USD), 2020, 2025 & 2034
  • Figure 7: Global: Generic Drug Delivery Market: Inhalers (in Million USD), 2020, 2025 & 2034
  • Figure 8: Global: Generic Injectables Market: Value Trends (in Billion USD), 2020-2025
  • Figure 9: Global: Generic Injectables Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Generic Injectables Market: Breakup by Therapeutic Area (in %), 2025
  • Figure 11: Global: Generic Injectables Market: Breakup by Container (in %), 2025
  • Figure 12: Global: Generic Injectables Market: Breakup by Distribution Channel (in %), 2025
  • Figure 13: Global: Generic Injectables Market Forecast: Value Trends (in Billion USD), 2026-2034
  • Figure 14: Global: Generic Injectables Industry: SWOT Analysis
  • Figure 15: Global: Generic Injectables Industry: Value Chain Analysis
  • Figure 16: Global: Generic Injectables Industry: Porter's Five Forces Analysis
  • Figure 17: North America: Generic Injectables Market (in Million USD), 2020 & 2025
  • Figure 18: North America: Generic Injectables Market Forecast (in Million USD), 2026-2034
  • Figure 19: Europe: Generic Injectables Market (in Million USD), 2020 & 2025
  • Figure 20: Europe: Generic Injectables Market Forecast (in Million USD), 2026-2034
  • Figure 21: Asia: Generic Injectables Market (in Million USD), 2020 & 2025
  • Figure 22: Asia: Generic Injectables Market Forecast (in Million USD), 2026-2034
  • Figure 23: Latin America: Generic Injectables Market (in Million USD), 2020 & 2025
  • Figure 24: Latin America: Generic Injectables Market Forecast (in Million USD), 2026-2034
  • Figure 25: Middle East and Africa: Generic Injectables Market (in Million USD), 2020 & 2025
  • Figure 26: Middle East and Africa: Generic Injectables Market Forecast (in Million USD), 2026-2034
  • Figure 27: Global: Generic Injectables (Oncology) Market: Value Trends (in Million USD), 2020 & 2025
  • Figure 28: Global: Generic Injectables (Oncology) Market Forecast: Value Trends (in Million USD), 2026-2034
  • Figure 29: Global: Generic Injectables (Anaesthesia) Market: Value Trends (in Million USD), 2020 & 2025
  • Figure 30: Global: Generic Injectables (Anaesthesia) Market Forecast: Value Trends (in Million USD), 2026-2034
  • Figure 31: Global: Generic Injectables (Anti-infectives) Market: Value Trends (in Million USD), 2020 & 2025
  • Figure 32: Global: Generic Injectables (Anti-infectives) Market Forecast: Value Trends (in Million USD), 2026-2034
  • Figure 33: Global: Generic Injectables (Parenteral Nutrition) Market: Value Trends (in Million USD), 2020 & 2025
  • Figure 34: Global: Generic Injectables (Parenteral Nutrition) Market Forecast: Value Trends (in Million USD), 2026-2034
  • Figure 35: Global: Generic Injectables (Cardiovascular) Market: Value Trends (in Million USD), 2020 & 2025
  • Figure 36: Global: Generic Injectables (Cardiovascular) Market Forecast: Value Trends (in Million USD), 2026-2034
  • Figure 37: Global: Generic Injectables (Vials) Market: Value Trends (in Million USD), 2020 & 2025
  • Figure 38: Global: Generic Injectables (Vials) Market Forecast: Value Trends (in Million USD), 2026-2034
  • Figure 39: Global: Generic Injectables (Ampoules) Market: Value Trends (in Million USD), 2020 & 2025
  • Figure 40: Global: Generic Injectables (Ampoules) Market Forecast: Value Trends (in Million USD), 2026-2034
  • Figure 41: Global: Generic Injectables (Premix) Market: Value Trends (in Million USD), 2020 & 2025
  • Figure 42: Global: Generic Injectables (Premix) Market Forecast: Value Trends (in Million USD), 2026-2034
  • Figure 43: Global: Generic Injectables (Prefilled Syringes) Market: Value Trends (in Million USD), 2020 & 2025
  • Figure 44: Global: Generic Injectables (Prefilled Syringes) Market Forecast: Value Trends (in Million USD), 2026-2034
  • Figure 45: Global: Generic Injectables Market: Sales through Hospitals (in Million USD), 2020 & 2025
  • Figure 46: Global: Generic Injectables Market Forecast: Sales through Hospitals (in Million USD), 2026-2034
  • Figure 47: Global: Generic Injectables Market: Sales through Retail Pharmacy (in Million USD), 2020 & 2025
  • Figure 48: Global: Generic Injectables Market Forecast: Sales through Retail Pharmacy (in Million USD), 2026-2034
  • Figure 49: Generic Injectables Manufacturing Process: Conversion Rate of Feedstocks
  • Figure 50: Generic Injectables Manufacturing: Detailed Process Flow
  • Figure 51: Generic Injectables Manufacturing: Production Cost Breakup (in %)
  • Figure 52: Generic Injectables Industry: Profit Margins at Various Levels of the Supply Chain
  • Figure 53: Generic Injectables Manufacturing Plant: Proposed Plant Layout
  • Figure 54: Generic Injectables Manufacturing Plant: Breakup of Capital Costs (in %)

List of Tables

  • Table 1: Global: Generic Drug Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Generic Drug Market Forecast: Breakup by Region, 2026-2034
  • Table 3: Global: Generic Drug Market: Revenues of Key Players (in Million USD), 2020
  • Table 4: Global: Generic Injectables Market: Key Industry Highlights, 2025 and 2034
  • Table 5: Global: Generic Injectables Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Generic Injectables Market Forecast: Breakup by Therapeutic Area (in Million USD), 2026-2034
  • Table 7: Global: Generic Injectables Market Forecast: Breakup by Container (in Million USD), 2026-2034
  • Table 8: Global: Generic Injectables Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 9: Generic Injectables Manufacturing Plant: Costs Related to Land and Site Development (in USD)
  • Table 10: Generic Injectables Manufacturing Plant: Costs Related to Civil Works (in USD)
  • Table 11: Generic Injectables Manufacturing Plant: Costs Related to Machinery Unit (in USD)
  • Table 12: Generic Injectables Manufacturing Plant: Raw Material Requirements (Kg/Day) and Expenditures (USD/Kg)
  • Table 13: Generic Injectables Manufacturing Plant: Costs Related to Salaries and Wages (in USD)
  • Table 14: Generic Injectables Manufacturing Plant: Costs Related to Other Capital Investments (in USD)
  • Table 15: Details of Financial Assistance Offered by Financial Institutions
  • Table 16: Generic Injectables Manufacturing Plant: Capital Costs (in USD)
  • Table 17: Generic Injectables Manufacturing Plant: Techno-Economic Parameters (in USD)
  • Table 18: Generic Injectables Manufacturing Plant: Taxation and Depreciation (in USD)
  • Table 19: Generic Injectables Manufacturing Plant: Income Projections (in USD)
  • Table 20: Generic Injectables Manufacturing Plant: Expenditure Projections (in USD)
  • Table 21: Generic Injectables Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability (in USD)
  • Table 22: Generic Injectables Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability (in USD)
  • Table 23: Generic Injectables Manufacturing Plant: Profit and Loss Account (in USD)